Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Elanco (ELAN)

NYSE Health Care Pharmaceuticals S&P MidCap 400
$25.74
+2.06 (+8.70%)
Close of Nov 06, 2026 · end-of-day data
Source: Elanco's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 06, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$2.91B$2.89B$3.07B$3.07B$3.27B$4.76B$4.41B$4.42B$4.44B$4.71B
Cost of revenue$1.41B$1.49B$1.57B$1.47B$1.67B$2.13B$1.91B$1.93B$2.00B$2.12B
Gross profit$1.50B$1.40B$1.49B$1.60B$1.61B$2.63B$2.50B$2.49B$2.44B$2.59B
Research & development$265.80M$251.70M$246.60M$270.00M$329.00M$369.00M$321.00M$327.00M$344.00M$368.00M
Selling, general & admin$784.80M$779.80M$735.20M$760.00M$997.00M$1.40B$1.26B$1.28B$1.31B$1.43B
Interest expense$0$0$29.60M$79.00M$150.00M$236.00M$241.00M$277.00M——
Pre-tax income-$22.40M-$232.60M$114.10M$78.00M-$677.00M-$571.00M-$72.00M-$1.20B$488.00M-$224.00M
Income tax$25.50M$78.10M$27.60M$10.00M-$103.00M-$88.00M$6.00M$36.00M$150.00M$8.00M
Net income-$47.90M-$310.70M$86.50M$68.00M-$574.00M-$483.00M-$78.00M-$1.23B$338.00M-$232.00M
EPS (basic)$-0.16$-1.06$0.28$0.18$-1.30$-0.99$-0.16$-2.50$0.68$-0.47
EPS (diluted)$-0.16$-1.06$0.28$0.18$-1.30$-0.99$-0.16$-2.50$0.68$-0.47
Diluted shares293.30M293.30M313.70M370.30M441.40M487.20M488.30M492.30M497.30M496.40M
Gross margin51.6%48.3%48.7%52.1%49.1%55.2%56.6%56.3%54.9%55.0%
Net margin-1.6%-10.8%2.8%2.2%-17.5%-10.1%-1.8%-27.9%7.6%-4.9%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$258.80M$323.40M$474.80M$334.00M$495.00M$638.00M$345.00M$352.00M$468.00M$545.00M
Receivables—$567.40M$651.80M$816.90M$872.00M$833.00M$797.00M$842.00M$805.00M$873.00M
Inventory—$1.06B$1.00B$1.05B$1.58B$1.37B$1.54B$1.74B$1.57B$1.74B
Total current assets—$2.12B$2.50B$2.37B$3.42B$3.27B$3.28B$3.41B$3.21B$3.46B
Goodwill—$2.97B$2.96B$2.99B$6.22B$6.17B$5.99B$5.09B$4.41B$4.78B
Total assets—$8.94B$8.96B$8.99B$17.69B$16.48B$15.49B$14.36B$12.61B$13.36B
Total current liabilities—$643.10M$970.70M$818.50M$2.08B$1.65B$1.70B$1.24B$1.31B$1.60B
Short-term debt—$0$29.00M$24.50M$555.00M$294.00M$388.00M$38.00M$44.00M$74.00M
Long-term debt—$0$2.44B$2.33B$5.57B$6.03B$5.45B$5.74B$4.28B$3.76B
Total debt—$0$2.47B$2.35B$6.13B$6.32B$5.84B$5.77B$4.32B$3.84B
Total liabilities—$1.16B$3.76B$3.44B$9.22B$8.97B$8.20B$8.14B$6.52B$6.81B
Shareholders' equity$7.02B$7.78B$5.20B$5.54B$8.46B$7.51B$7.29B$6.22B$6.10B$6.55B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$155.90M$173.80M$487.30M$224.00M-$41.00M$483.00M$452.00M$271.00M$541.00M$560.00M
Capital expenditures$110.30M$98.60M$134.50M$140.00M$135.00M$159.00M$171.00M$140.00M$147.00M$276.00M
Free cash flow$45.60M$75.20M$352.80M$84.00M-$176.00M$324.00M$281.00M$131.00M$394.00M$284.00M
Investing cash flow-$182.10M-$964.60M-$127.00M-$235.00M-$4.78B-$530.00M-$179.00M-$169.00M$1.16B-$279.00M
Financing cash flow-$149.60M$847.50M-$35.20M-$305.00M$4.95B$210.00M-$549.00M-$83.00M-$1.49B-$275.00M
Stock-based compensation$20.40M$25.00M$26.00M$49.00M$47.00M$66.00M$59.00M$46.00M$55.00M$68.00M
Depreciation & amortization$254.40M$318.40M$296.00M$314.00M$517.00M$716.00M$682.00M$694.00M$662.00M$680.00M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.